Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance

As Humira biosimilars enter the U.S. market in a steady stream, AbbVie execs say they're pleased with how the situation is playing out. Still, the company is weathering hefty revenue declines for that drug and another key medicine in its portfolio.